Suppr超能文献

基于结构的 SD-36 发现:一种强效、选择性且有效的 STAT3 蛋白 PROTAC 降解剂。

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.

出版信息

J Med Chem. 2019 Dec 26;62(24):11280-11300. doi: 10.1021/acs.jmedchem.9b01530. Epub 2019 Dec 10.

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and an attractive therapeutic target for cancer and other human diseases. Despite 20 years of persistent research efforts, targeting STAT3 has been very challenging. We report herein the structure-based discovery of potent small-molecule STAT3 degraders based upon the proteolysis targeting chimera (PROTAC) concept. We first designed SI-109 as a potent, small-molecule inhibitor of the STAT3 SH2 domain. Employing ligands for cereblon/cullin 4A E3 ligase and SI-109, we obtained a series of potent PROTAC STAT3 degraders, exemplified by SD-36. SD-36 induces rapid STAT3 degradation at low nanomolar concentrations in cells and fails to degrade other STAT proteins. SD-36 achieves nanomolar cell growth inhibitory activity in leukemia and lymphoma cell lines with high levels of phosphorylated STAT3. A single dose of SD-36 results in complete STAT3 protein degradation in xenograft tumor tissue and normal mouse tissues. SD-36 achieves complete and long-lasting tumor regression in the Molm-16 xenograft tumor model at well-tolerated dose-schedules. SD-36 is a potent, selective, and efficacious STAT3 degrader.

摘要

信号转导子和转录激活因子 3(STAT3)是一种转录因子,是癌症和其他人类疾病的有吸引力的治疗靶点。尽管经过 20 年的持续研究努力,靶向 STAT3 一直极具挑战性。我们在此报告了基于蛋白水解靶向嵌合体(PROTAC)概念的强效小分子 STAT3 降解剂的基于结构的发现。我们首先设计了 SI-109,作为 STAT3 SH2 结构域的有效小分子抑制剂。我们使用 cereblon/cullin 4A E3 连接酶配体和 SI-109,得到了一系列强效的 PROTAC STAT3 降解剂,以 SD-36 为例。SD-36 在细胞中以低纳摩尔浓度快速诱导 STAT3 降解,并且不会降解其他 STAT 蛋白。SD-36 在具有高磷酸化 STAT3 水平的白血病和淋巴瘤细胞系中实现了纳摩尔级的细胞生长抑制活性。单次给予 SD-36 可导致异种移植肿瘤组织和正常小鼠组织中 STAT3 蛋白完全降解。SD-36 在可耐受剂量方案下,在 Molm-16 异种移植肿瘤模型中实现了完全和持久的肿瘤消退。SD-36 是一种有效、选择性和有效的 STAT3 降解剂。

相似文献

1
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
J Med Chem. 2019 Dec 26;62(24):11280-11300. doi: 10.1021/acs.jmedchem.9b01530. Epub 2019 Dec 10.
2
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.
Cancer Cell. 2019 Nov 11;36(5):498-511.e17. doi: 10.1016/j.ccell.2019.10.002.
6
Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Biochem Biophys Res Commun. 2020 Jan 22;521(4):833-839. doi: 10.1016/j.bbrc.2019.11.007. Epub 2019 Nov 7.
9
Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
J Med Chem. 2024 Jun 13;67(11):9194-9213. doi: 10.1021/acs.jmedchem.4c00335. Epub 2024 Jun 3.
10
Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Bioorg Chem. 2021 Oct;115:105238. doi: 10.1016/j.bioorg.2021.105238. Epub 2021 Aug 8.

引用本文的文献

1
Discovery of a potent and selective PROTAC degrader for STAT3.
RSC Med Chem. 2025 Jul 31. doi: 10.1039/d5md00260e.
2
Transcription Factors and Methods for the Pharmacological Correction of Their Activity.
Int J Mol Sci. 2025 Jul 2;26(13):6394. doi: 10.3390/ijms26136394.
3
Advancing Design Strategy of PROTACs for Cancer Therapy.
MedComm (2020). 2025 Jun 25;6(7):e70258. doi: 10.1002/mco2.70258. eCollection 2025 Jul.
4
Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor Degradation.
Cancers (Basel). 2025 Jun 3;17(11):1871. doi: 10.3390/cancers17111871.
6
Cellular parameters shaping pathways of targeted protein degradation.
Commun Biol. 2025 May 2;8(1):691. doi: 10.1038/s42003-025-08104-w.
9
The Peptide PROTAC Modality: A New Strategy for Drug Discovery.
MedComm (2020). 2025 Mar 24;6(4):e70133. doi: 10.1002/mco2.70133. eCollection 2025 Apr.

本文引用的文献

1
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.
Cancer Cell. 2019 Nov 11;36(5):498-511.e17. doi: 10.1016/j.ccell.2019.10.002.
2
Targeted protein degradation: elements of PROTAC design.
Curr Opin Chem Biol. 2019 Jun;50:111-119. doi: 10.1016/j.cbpa.2019.02.022. Epub 2019 Apr 17.
6
Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Pharmacol Ther. 2018 Nov;191:74-91. doi: 10.1016/j.pharmthera.2018.06.006. Epub 2018 Jun 20.
7
High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction.
J Med Chem. 2018 Mar 8;61(5):1934-1950. doi: 10.1021/acs.jmedchem.7b01455. Epub 2018 Feb 26.
8
Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. doi: 10.1038/nrclinonc.2018.8. Epub 2018 Feb 6.
9
Antisense oligonucleotides: the next frontier for treatment of neurological disorders.
Nat Rev Neurol. 2018 Jan;14(1):9-21. doi: 10.1038/nrneurol.2017.148. Epub 2017 Dec 1.
10
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Cell Chem Biol. 2018 Jan 18;25(1):78-87.e5. doi: 10.1016/j.chembiol.2017.09.010. Epub 2017 Nov 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验